In vitro and in vivo pharmacokinetic studies of Bulaquine (Analogue of Primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey - Highlighting species similarities and differences

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 5, 2007, Pages 209-227

  Mehrotra, Nitin ^a,b   Lal, Jawahar ^a   Puri, Sunil Kumar ^a   Madhusudanan, Kunnath P ^a   Gupta, Ram Chandra ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bulaquine; Pharmacokinetics; Primaquine; Protein binding; Simulated gastric fluid

Indexed keywords

ANTIMALARIAL AGENT; BULAQUINE; DRUG METABOLITE; PRIMAQUINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RABBIT; RAT; RHESUS MONKEY; SIMULATION; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; STOMACH JUICE;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; ERYTHROCYTES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; PRIMAQUINE; PROTEIN BINDING; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SOLUTIONS; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 34547509879     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.547     Document Type: Article

References (31)

1. Schmidt LH, Genther CS. The antimalarial properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, daraprim. J Pharmacol Exp Ther 1953; 107: 61-91.
2. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 1981; 59: 391-395.
3. Bhat BK, Seth M, Bhaduri AP. Recent developments in 8-aminoquinoline antimalarials. Prog Drug Res 1984; 28: 197-231.
4. Puri SK, Srivastava R, Pandey VC, Sethi N, Dutta GP. Methemoglobin toxicity and hematological studies on malaria anti-relapse compound CDRI 80/53 in dogs. Am J Trop Med Hyg 1989; 41: 638-642.
5. Dutta GP, Puri SK, Bhaduri AP, Seth M. Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg 1989; 41: 635-637.
6. Paliwal JK, Gupta RC, Grover PK. Simultaneous determination of a new antimalarial agent, CDRI compound 80/53, and its metabolite primaquine in serum by high-performance liquid chromatography. J Chromatogr 1993; 616: 155-160.
7. Paliwal JK, Gupta RC. A rapid and sensitive high performance liquid chromatographic assay of the new antimalarial compound 80/53 in serum with a novel sample clean-up method and its pharmacokinetics in rabbits. J Pharm Biomed Anal 1998; 17: 775-783.
8. Lal J, Mehrotra N, Gupta RC. Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method - a pilot study. J Pharm Biomed Anal 2003; 32: 141-150.
9. Mehrotra N, Madabushi R, Lal J, Madhusudanan KP, Gupta RC. Liquid chromatography-tandem mass spectrometric assay with a novel method of quantitation for the simultaneous determination of bulaquine and its metabolite, primaquine, in monkey plasma. J Chromatogr B Anal Technol Biomed Life Sci 2003; 793: 253-263.
10. USP 25, NF 20, 2002, United States Pharmacopeial Convention Inc., Turnbrook Parkway, MD.
11. Khurana M, Paliwal JK, Kamboj VP, Gupta RC. Binding of centchroman with human serum as determined by charcoal adsorption method. Int J Pharm 1999; 192: 109-114.
12. Yuan J, Yang DC, Birkmeier J, Stolzenbach J. Determination of protein binding by in vitro charcoal adsorption. J Pharmacokinet Biopharm 1995; 23: 41-55.
13. Hamberger C, Urien S, Barre J, et al. Distribution of cyclosporin A between blood cells and plasma of cardiac and renal transplant recipients. Ther Drug Monit 1988; 10: 28-33.
14. Veng Pedersen P. Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon. J Pharm Sci 1981; 70: 32-38.
15. Suverkrup R. Discontinuous absorption processes in pharmacokinetic models. J Pharm Sci 1979; 68: 1395-1400.
16. Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP. Bioavailability of cimetidine in man. Gastroenterology 1978; 74: 360-365.
17. Oberle RL, Amidon GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 1987; 15: 529-544.
18. Garg DC, Weidler DJ, Eshelman FN. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther 1983; 33: 445-452.
19. Bergstrom RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine kinetics in normal subjects. Clin Pharmacol Ther 1981; 30: 404-413.
20. Plusquellec Y, Campistron G, Staveris S, et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 1987; 15: 225-239.
21. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
22. Mummaneni V, Dressman JB. Intestinal uptake of cimetidine and ranitidine in rats. Pharm Res 1994; 11: 1599-1604.
23. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 2004; 30: 221-229.
24. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 23: 1008-1021.
25. Stevens JC, Shipley LA, Cashman JR, Vandenbranden M, Wrighton SA. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab Dispos 1993; 21: 753-760.
26. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
27. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375-1384.
28. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992; 51: 465-473.
29. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49: 279-295.
30. Trenholme GM, Williams RL, Rieckmann KH, Frischer H, Carson PE. Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther 1976; 19: 459-467.
31. White NJ, Looareesuwan S, Warrell DA, et al. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 1983; 32: 1-5.